Research press release


Nature Medicine

Medical research: Vision partially restored in blind patient after optogenetic therapy



J Sahel、B Roskaたちは、現在進行中の第1/2a相臨床試験の当初の結果について報告している。彼らは、視力を失った58歳の男性RP患者1人の片方の目に、光遺伝学的センサーChrimsonRをコードするアデノ随伴ウイルスベクター(遺伝子治療に使われる)を注射し、治療用に作製したゴーグルを介して光刺激を行った。このゴーグルには特殊なカメラが備わっていて、視作業を行う間、これが視覚世界からの画像を捉えて光パルスに変換し、網膜へとリアルタイムで投射して、遺伝子導入した細胞を活性化した。この治療は耐容性が良好で患者がよく我慢できるものであり、これまで失明していたこの患者は、光刺激ゴーグルを装着している間は、治療を施した目で、さまざまな物体を認識し、数え、位置を知り、触ることができた。


A blind patient diagnosed with retinitis pigmentosa (RP) almost 40 years ago experienced partial recovery of vision after a novel optogenetic treatment, reports a case study published in Nature Medicine. This is the first reported case of functional recovery in a neurodegenerative disease after optogenetic therapy (which controls specific cells through pulses of light, after the cells have been genetically modified to respond to such stimulation).

RP is a neurodegenerative eye disease that breaks down the cells in the retina that are receptive to light and can lead to complete blindness. There is no approved treatment for RP, except for a gene-replacement therapy that works only on an early-onset form of the disease.

José Sahel, Botond Roska and colleagues describe the initial results of an ongoing phase 1/2a study in which they injected an adeno-associated viral vector (used to facilitate gene therapy) encoding the optogenetic sensor ChrimsonR into one eye of a blind, 58-year-old male patient with RP, combined with light stimulation via engineered goggles. The goggles had a special camera that captured images from the visual world and transformed them into light pulses that were then projected onto the retina in real time in order to activate the modified cells during visual tasks. This treatment approach was well tolerated, and the previously blind patient was able to recognize, count, locate and touch different objects with the treated eye while wearing the light-stimulating goggles.

The authors conclude that optogenetic therapy may be beneficial in restoring visual function in people with RP-related blindness. However, further results from this trial are needed for a clearer picture of the safety and efficacy of this approach.

doi: 10.1038/s41591-021-01351-4


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。